Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

able, less current portion - 119,000

Capital lease obligation, less current portion 17,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock-$.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock-$.001 par value; authorized

325,000,000 shares; outstanding -

226,210,617 and 196,112,201, respectively 226,000 196,000

Additional paid-in capital 245,982,000 224,453,000

Accumulated deficit (224,677,000) (207,660,000)

Total stockholders' equity 21,531,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $28,241,000 $22,997,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED NINE MONTHS ENDED

January 31, January 31, January 31 January 31,

2008 2007 2008 2007

Unaudited Unaudited Unaudited Unaudited

REVENUES:

Contract

manufacturing

revenue $1,662,000 $347,000 $5,146,000 $1,381,000

License revenue 13,000 16,000 46,000 87,000

Total revenues 1,675,000 363,000 5,192,000 1,468,000

COSTS AND EXPENSES:

Cost of contract

manufacturing 1,289,000 223,000 3,872,000 1,247,000

Research and

development 4,941,000 3,907,000 13,665,000 11,868,000

Selling, general

and administrative 1,847,000 1,513,000 5,498,000 4,824,000

Total costs

and expenses
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Graphite Metallizing Corporation announces a ... in stainless steel pillow blocks. This series combines ... the application and installation versatility of pillow blocks. ... work exceptionally well when submerged in water, water-soluble ... as acids, alkalies, hydrocarbons, black liquor, and liquid ...
(Date:5/23/2013)... -- Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a ... and therapeutics, announced today that StemCyte has become an ... car driven by James Jakes . ... 2013 season.   StemCyte, Inc. and Rahal Letterman ... umbilical cord blood banking and its educational initiative ,Stars ...
(Date:5/23/2013)... 2013 VG Energy, an agricultural biotech ... Renewable Research to conduct field trials using LipidMax ... is a majority owned subsidiary of VG Life ... Energy,s exclusively licensed compound LipidMax selectively inhibits certain ... plants, possessing a wide variety of applications including ...
(Date:5/23/2013)... May 23, 2013 BioTrends Research Group, ... firms for specialized biopharmaceutical issues, finds that, unaided, ... disease specialists reported that in the past six ... delaying treatment) in anticipation of the next generation ... ago, when only 6 percent reported that they ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... capital for clinical trials, ZyStor Therapeutics will be ... venture capital forum next month in Overland Park, Kan. ... like to raise an additional $15 million or more in ... begin in early 2008. , ,The company, located in ...
... - During a meeting with U.S. Health and ... Wisconsin employers and healthcare organizations pledged to support health ... in the health information technology products used by their ... of an effort to support a national initiative aimed ...
... that a return to profitability won't happen until later this ... of $258.5 million, or $7.67 per diluted share, in a ... of financial reporting errors. , ,The loss, which included a ... million, or $6.85 per share, compares to a net loss ...
Cached Biology Technology:ZyStor seeks to raise $15M for clinical trials 2ZyStor seeks to raise $15M for clinical trials 3Wisconsin firms pledge to support healthcare IT standards 2Merge Healthcare suffers $258M loss in `06 2
(Date:5/23/2013)... of Public Health at Emory University, along with ... received a $4 million grant over four years ... (Health and Exposome Research Center: Understanding Lifetime Exposures). ... awarded in the United States. , The ... of Environmental Health Sciences (NIEHS) of the National ...
(Date:5/23/2013)... 2013) A new report from the Institute of ... engage in at least 60 minutes of vigorous or ... more than half of American youth meet current evidence-based ... moderate intensity physical activity daily, according to the report, ... in school for nearly half of their waking hours, ...
(Date:5/23/2013)... when microbial pathogens are growing increasingly resistant to the ... of Wisconsin scientists has synthesized a potent new class ... staph infections. , Writing online in the Journal ... by University of Wisconsin-Madison chemistry Professor Helen Blackwell describes ... of Staphylococcus aureus , a bacterium at the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide students with daily physical activity, IOM recommends 2University of Wisconsin chemists find new compounds to curb staph infection 2
... release is available in German . ... that are crucial in fighting pathogen assault. Researchers ... the Helmholtz Centre for Environmental Research (UFZ) characterized ... class II locus in a tailed amphibian. Unlike ...
... Manchester has been successful in gaining major European ... millions of biological samples, such as DNA, can ... across Europe. The Centre for Integrated Genomic ... Translational Medicine, is playing a key role in ...
... CA Nitrogen is essential to all life on Earth, and ... determine how ecosystems respond to global warming. But certain aspects ... puzzled scientists, defying, in a sense, the laws of supply ... atmosphere often thrive where it is readily available in the ...
Cached Biology News:New findings on immune system in amphibians 2Manchester clears first hurdle in €170 million biobank building boom 2Researchers explain nitrogen paradox in forests 2